bpc-157 human clinical trials evidence review safety fda warning Is Banned? Oral vs. Injectable Forms Explained FDA scientists flag concerns with

Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance

Bartnik A, Nirmal AJ, Yang SY

Below are five other mechanisms of action that BPC-157 might perform

High-dose oral supplements (often 10002000 micrograms daily) or intramuscular injections (typically 1mg hydroxocobalamin) used to treat pernicious anaemia or deficiency states can temporarily elevate serum levels

Pittaway, Donald E., et al

Investigators have assessed multiple administration routes, including subcutaneous, intramuscular, intravenous, oral, and topical delivery in experimental models